Clinical Trial Update: Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of Phase 1/2 testing of a topical NF-kappaB decoy for atopic dermatitis, sponsored by Anesiva, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Topical NF-kappaB decoy

Snippet

Sponsor: Anesiva, Inc. | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED